Inovio announces results from Pennvax-GP Phase 1 study
Inovio announced that its synthetic HIV vaccine Pennvax-GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. In this reported study, Pennvax-GP plasmids were delivered intradermally or intramuscularly with Cellectra device in healthy volunteers. More specifically, the study results demonstrated that Pennvax-GP delivered intradermally, or ID, with Cellectra generated equivalent or superior immune responses compared to the delivery via intramuscular, or IM, route using the same delivery device, with ID delivery using only one-fifth of the dose compared to IM delivery. These results are from a study supported by the HIV Vaccine Trials Network, or HVTN, and the National Institute of Allergy and Infectious Diseases part of the National Institutes of Health in collaboration with Inovio.